| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.075 | 0.05 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.05 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |